Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.64 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.64 |
| ▸ | GAK | O14976 | 2/20 | 0.64 |
| ▸ | ABL1 | P00519 | 2/20 | 0.64 |
| ▸ | LCK | P06239 | 2/20 | 0.64 |
| ▸ | MET | P08581 | 2/20 | 0.64 |
| ▸ | PHKG2 | P15735 | 2/20 | 0.64 |
| ▸ | BLK | P51451 | 2/20 | 0.64 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.64 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.64 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.64 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 0.64 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 0.64 |
| ▸ | CIT | O14578 | 1/20 | 0.64 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.64 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.64 |
| ▸ | STK10 | O94804 | 1/20 | 0.64 |
| ▸ | LYN | P07948 | 1/20 | 0.64 |
| ▸ | RET | P07949 | 1/20 | 0.64 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17503015 | 0.97 | EGFR (0.67) | EGFRERBB2GAKABL1LCK | |
| Bromide SCHEMBL868455 | 0.97 | EGFR (0.67) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL17503009 | 0.88 | EGFR (0.63) | EGFRERBB2GAKLCKERBB4 | |
| Bromide SCHEMBL868424 | 0.88 | EGFR (0.63) | EGFRERBB2GAKLCKERBB4 | |
| SCHEMBL17412655 | 0.86 | EGFR (0.68) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL18162786 | 0.83 | EGFR (0.81) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL29779432 | 0.83 | EGFR (0.81) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL17826933 | 0.81 | EGFR (0.68) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL17448813 | 0.80 | EGFR (0.86) | EGFRERBB2GAKABL1LCK | |
| SCHEMBL28418910 | 0.80 | EGFR (0.89) | EGFRERBB2GAKABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | claimed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | claimed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | claimed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | claimed |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | RAIN THERAPEUTICS INC. | 2021-11-11 | — | — | US | disclosed |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2020-08-27 | — | — | US | disclosed |
| EP-3031807-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | Auckland UniServices Limited (NZ) | 2016-06-15 | — | — | EP | disclosed |
| EP-2406262-B1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LTD (NZ) | 2016-02-17 | — | — | EP | disclosed |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2016-01-07 | — | — | US | disclosed |
| US-9073916-B2 | Prodrug forms of kinase inhibitors and their use in therapy | AUCKLAND UNISERVICES LIMITED (NZ) | 2015-07-07 | — | — | US | disclosed |
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | AUCKLAND UNISERVICES LIMITED (NZ) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077811-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 48/4885ERBB2 7/4885GAK 413/4885 |
| US-20200268759-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN DRUG-RESISTANT CANCERS | EGFR, BRCA1, ERBB2 | EGFR 1/4885ERBB2 3/4885GAK 650/4885 |
| US-20160002222-A1 | PRODRUG FORMS OF KINASE INHIBITORS AND THEIR USE IN THERAPY | NTRK3, TK1, TNNI3K | EGFR 41/4885ERBB2 7/4885GAK 534/4885 |
| US-20210346383-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING HER-DRIVEN CANCERS | EGFR, VHL, MYC | EGFR 1/4885ERBB2 7/4885GAK 676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.